Abstract PS7-24: Characteristics of HR+/HER2- patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)

Autor: César A. Rodríguez, Maria Jose Echarri, Isabel Alvarez, Carlos Poblete Jara, Federico Rojo, I Garau, Diana Moreno, Antonio Antón, Mireia Margeli, Josefina Cruz, Ariadna Tibau, M. J. Escudero, Purificación Martínez, Ángel L Guerrero, Silvia Antolín, Sara López-Tarruella, Catalina Falo, Marta Mori, Álvaro Rodríguez-Lescure, Susana Bezares

Publikováno v: Cancer Research. 81:PS7-24

Background: The RegistEM study is a non-interventional cohort study that will provide prospective data from >1,800 advanced breast cancer (ABC) patients (pts), either after recurrence or as first diagnosis in 38 Spanish sites. Primary objective is th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::136a5cb149a909a25006fca6e1b97a81
https://doi.org/10.1158/1538-7445.sabcs20-ps7-24

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Autor: M Melé, Serafin Morales, Noelia Martínez, Jordi Canes, Begoña Bermejo, I Garau, Paolo Nuciforo, Patricia Villagrasa, Maria Jose Echarri, Antonia Perelló, Barbara Adamo, Blanca Gonzalez-Farre, Silvia Vazquez, Tomás Pascual, Xavier Gonzalez, Santiago Escrivá-de-Romaní, Patricia Galván, Sonia Pernas, Eva Ciruelos, Mafalda Oliveira, D. Martinez, Javier Cortes, Laia Paré, Alvaro Montaño, Aleix Prat, Eduardo Martínez, Estela Vega, Luis Manso

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
CLINICAL CANCER RESEARCH
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón

Purpose:To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer.Patients and Methods:PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::282c78a6a680ca56bae282fb9e4e061e
https://doi.org/10.1158/1078-0432.ccr-20-0844

Palbociclib combined with endocrine therapy in heavily pretreated HR + /HER2 - advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

Autor: Carlos E. Robles, Amparo Oltra, Raquel Bratos, Fernando Salvador Moreno, Isabel Gallegos, Iñaki Álvarez-Busto, Manuel Ruiz-Borrego, Salvador Blanch, Marta Santisteban, Elisa Garcia-Garre, José E. Alés-Martínez, Diego Malón, Maria Gonzalez-Cao, Cristina Reboredo, Maria Jose Echarri, Serafin Morales, Juan I. Delgado-Mingorance, Ana Isabel Ballesteros, César A. Rodríguez, Blanca Hernando, Miguel Angel Cabrera, Mafalda Oliveira, Cristina Hernando, Raquel Andrés, Isabel Echeverría, Lucía González-Cortijo, Elena Aguirre, Marta Legeren, Rafael López, Antonio Llombart-Cussac, Estela Vega, Elena Galve, Luis Manso, Sonia Servitja, María Galán

Publikováno v: Scientia
The Breast : Official Journal of the European Society of Mastology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Breast (Edinburgh, Scotland)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
BREAST
r-FISABIO. Repositorio Institucional de Producción Científica
Breast, Vol 54, Iss, Pp 286-292 (2020)

Background: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavilypretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/ HER2(-)) metastatic breast cancer (mBC) patients durin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d3c7a63a16cdef7943832a5179a8480
https://hdl.handle.net/11351/6372

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Autor: T. Bachelot, E. Ciruelos, A. Schneeweiss, F. Puglisi, T. Peretz-Yablonski, I. Bondarenko, S. Paluch-Shimon, A. Wardley, J.-L. Merot, Y. du Toit, V. Easton, N. Lindegger, D. Miles, Kamel Bouzid, Mario Campone, Bruno Coudert, Zbigniew Nowecki, Hassan Errihani, Florence Dalenc, Ana Ferreira, Max Mano, Francesco Ricci, Haralabos Kalofonos, Claudia Andreetta, Filippo Montemurro, Sophie Barrett, Qingyuan Zhang, Dimitris Mavroudis, Juan Matus, Carlos Beato, Xichun Hu, Rabab Gaafar, Hamdy Abdel Azeem, Christophe Perrin, Johannes Ettl, Istvan Lang, Sunil Verma, Huiping Li, Etienne Brain, Oliver Hoffmann, Anna Cariello, Carlo Tondini, Taher Altwegeiri, Niklas Loman, Michael Lux, Antonio Frassoldati, Zeba Aziz, Fernando Salas, Joanna Streb, Andrzej Wronski, Salomón Menjón Beltrán, Irfan Cicin, Peter Schmid, Robert Laing, Zhongsheng Tong, Katalin Boer, Balazs Juhasz, Luca Gianni, Giuseppe Curigliano, Alejandro Juarez, Snezana Susnjar, Erika Matos, Ruchan Uslu, Hans Wildiers, Marcelo Cruz, Hugues Bourgeois, Raquel von Schumann, Salomón Stemmer, Flavia Morales Vásquez, Adriana Dominguez, Marek Wojtukiewicz, Jasna Trifunovic, Jose Juan Illarramendi, Laura Garcia, Yann Izarzugaza Peron, Maria Jose Echarri, Natliia Voitko, Duncan Wheatley, Simon Waters, Richard De Boer, Guy Jerusalem, Véronique Cocquyt, Carlos Barrios, Lawrence Panasci, Johanna Mattson, Minna Tanner, Michel Gozy, Georgios Vasilopoulos, Janos Revesz, Luciano Latini, Cesare Gridelli, Jesus Lazaro, Antonio Gonzalez, Agusti Barnadas Molins, Eduardo Martinez, Jesús Alarcón, Ana Arance, Leif Klint, Oleksiy Kovalyov, Richard Baird, Belinda Yeo, Nicole McCarthy, Richard Greil, Shusen Wang, Xavier Artignan, Paule Augereau, Ingolf Juhasz-Boess, Roger Ngan, Hadassah Goldberg, Francesco Di Costanzo, Francesco Ferraù, Eduardas Aleknavicius, Kamran Rashid, Luís Costa, Jose Angel Garcia, Luis Ruiz de la Cruz, Rafael López López, Olga Del Val, Ozgur Ozyilkan, Fathi Azribi, Mark Verrill, Nicholas Turner, Jane Beith, Andreas Petzer, Jurandyr Andrade, Vanessa Bernstein, Daniel Rayson, Ibtessam Saad Eldin, Mihaëla Achille, Volkmar Mueller, Alessandra Gennari, Stefano Cascinu, Marwan Ghosn, Nagi El-Saghir, Joan Van den Bosch, Rianne Oosterkamp, Monika Kukulska, Ignacio Pelaez, Carolina Hernandez, Maria del Mar Gordon, Elsa Dalmau, Jose Luis Alonso, Sercan Aksoy, Hasan Senol Coskun, Yaroslav Shparyk, Mohini Varughese, Udaiveer Panwar, Lisa Barraclough, Nicola Levitt, Jonathan Hicks, Anna Rigg, Mark Allen, Cecila Castillo, Luis Enrique Fein, Robin Stuart-Harris, Christian Singer, Herbert Stoeger, Sasha Smiljanic, Jifeng Feng, Miguel Cedeño, Jean Francois Berdah, Hubert Orfeuvre, Anthony Goncalves, Eva-Maria Grischke, Eike Simon, Steffen Wagner, Anna Efremidou, Konstantinos Papazisis, Ella Evron, Moshe Inbar, Noa Ben Baruch, David Geffen, Natalya Karminsky, Enzo Maria Ruggeri, Cavanna Luigi, Donatella Grasso, Elona Juozaityte, Jeronimo Rafael Rodriguez Cid, Henk Roerdink, Neelum Siddiqi, José Luís Passos Coelho, Elisa Garcia Garre, Andres Garcia, Noelia Martínez Jañez, Maria Helena Lopez Ceballos, Mireia Mele, María García, Alberto Arcediano, Karen McAdam, Timothy Perren, Wendy Taylor, Alison Humphreys, Raul Vera, Luis Alberto Kaen, Günther Steger, Johannes Andel, Jacques de Grève, Manon Huizing, Roberto Hegg, Anil Joy, Sandeep Sehdev, Riina Kütner, Johanna Ruohola, Nadine Dohollou, Jessica Grosjean, Philippe Laplaige, Rémy Largillier, Philippe Martin, Virginie Pottier, Jerome Alexandre, Bernd Christensen, Dirk-Michael Zahm, Fariba Khandan, Hans-Joachim Lueck, Georgios Fountzilas, Georgeta Fried, Alice Giacobino, Andrea Bonetti, Yanin Chavarri Guerra, Laurens Van Warmerdam, Annette Van der Velden, Suzan Vrijaldenhoven, Felix de Jongh, Milagros Cavero, Raquel Andres Conejero, Adolfo Murias, Salvador Saura, Amparo Oltra, Andres Redondo, Nuria Ribelles, Kilian Bachmeier, Johnathan Joffe, Prabir Chakraborti, Mark Beresford, Mohammad Butt, Christopher Poole, Gassan Yordi, Natasha Woodward, Gilberto Amorim, Nadia Califaretti, Susan Fox, Andre Robidoux, NanLi Li, Nenxiao Li, Jun Jiang, Tannia Soria, Peeter Padrik, Outi Saarni, Dominique Genet, Stéphanie Catala, Hugues Barletta, Luis Teixeira, Thomas Facchini, Tobias Hesse, Thorsten Kühn, Angelika Ober, Roland Repp, Willibald Schroeder, Dimitrios Pectasides, Gyorgy Bodoky, Zsuzsanna Kahan, Irina Jiveliouk, Ora Rosengarten, Oscar Alabiso, Mario Perez, Yes Van de Wouw, Jolanta Smok-Kalwat, Margarida Damasceno, Gabriela Sousa, Omalkhair Abulkhair, Antonio Antón Torres, Maria Purificación Martinez, Jesús Garcia Mata, Marta Santisteban Jesús Florián Jerico, Antonio Llombart, Rosa Sanchez, Juan Carlos Torrego, Clara Olier Garate, Cesar Rodriguez, Rosa Llorente, Diego Soto de Prado, Javier Cortés, Cristina Llorca, Antonio Galán, Gemma Viñas Villaro, Ulrik Narbe, Helena Granstam Bjömeklett, Sarah Westwell, Jackie Newby, Mariam Jafri, Robinson Rodríguez, Isabel Alonso

Background Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7394dbd3f670d60bcbd805c7b372138
https://hdl.handle.net/20.500.14017/e2dbbab9-c685-4110-8d14-e0e540d6de6b

Abstract OT2-02-06: Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial

Autor: Eduardo Martínez, Estela Vega, Antonia Perelló, Xavier Gonzalez, Noelia Martínez, Jordi Canes, Mafalda Oliveira, Javier Cortes, Pamela Céliz, M Melé, Maria Jose Echarri, I Garau, Eva Ciruelos, Silvia Vazquez, Begoña Bermejo, Patricia Villagrasa, Alvaro Montaño, Aleix Prat, Sonia Pernas, Blanca Cantos, Tomás Pascual

Publikováno v: Cancer Research. 80:OT2-02

Background: Efficacy Interim results from PATRICIA phase II trial in HER2+/HR+ advanced breast cancer (BC) showed that PAM50 luminal disease was associated with larger and clinically meaningful progression-free survival (PFS) following palbociclib, t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::acb65e91bb003772ff5909d0e7a4ca9b
https://doi.org/10.1158/1538-7445.sabcs19-ot2-02-06